about
Interleukin-6 in Schizophrenia-Is There a Therapeutic Relevance?Positive impact of prescribed physical activity on symptoms of schizophrenia: randomized clinical trial.Increase systemic levels of IL-23 as a possible constitutive marker in schizophrenia.Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse.The effect of antipsychotic drugs on nonspecific inflammation markers in the first episode of schizophrenia.IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis.
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Milica Milovan Borovcanin
@ast
Milica Milovan Borovcanin
@en
Milica Milovan Borovcanin
@es
Milica Milovan Borovcanin
@fr
Milica Milovan Borovcanin
@nl
Milica Milovan Borovcanin
@sl
type
label
Milica Milovan Borovcanin
@ast
Milica Milovan Borovcanin
@en
Milica Milovan Borovcanin
@es
Milica Milovan Borovcanin
@fr
Milica Milovan Borovcanin
@nl
Milica Milovan Borovcanin
@sl
prefLabel
Milica Milovan Borovcanin
@ast
Milica Milovan Borovcanin
@en
Milica Milovan Borovcanin
@es
Milica Milovan Borovcanin
@fr
Milica Milovan Borovcanin
@nl
Milica Milovan Borovcanin
@sl
P106
P1153
36161907400
P21
P31
P496
0000-0002-2992-814X